Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Jack Baniel is a pioneering urologic oncologist whose research focuses on advancing surgical and radiotherapeutic strategies for prostate and bladder cancers. His most impactful work includes a landmark Phase 1 trial (2022, 37 citations) demonstrating the safety and feasibility of neoadjuvant 177Lu-PSMA-I&T radionuclide therapy in high-risk prostate cancer patients prior to radical prostatectomy—a novel approach that integrates targeted molecular radiotherapy with surgery to improve outcomes. Dr. Baniel has also made significant contributions to robotic surgery, evidenced by a systematic review (2024, 9 citations) evaluating robot-assisted simple prostatectomy outcomes across varying prostate volumes, providing crucial guidance for surgical planning in benign prostatic hyperplasia. Additionally, his multicenter study (2017, 8 citations) comparing robot-assisted versus open radical cystectomy in muscle-invasive bladder cancer patients receiving perioperative chemotherapy offers valuable oncologic perspectives on surgical efficacy. With a career marked by innovative clinical trials and evidence-based surgical research, Dr. Baniel’s work directly impacts treatment paradigms, bridging the gap between advanced radiotherapy and minimally invasive urologic surgery. His findings continue to shape clinical decision-making for high-risk prostate and bladder cancer patients worldwide.